Programs

Surrozen is developing a broad pipeline of disease-specific antibodies to help gravely ill patients across multiple disease areas.

Our strategy is to harness the full breadth of Wnt potential by identifying disease states responsive to Wnt pathway modulation, design tissue-specific antibodies, and advance candidates into clinical development in indications with high unmet need.

Tissue

Indication

Platform Technology

Molecule

Discovery

Proof of Concept

Lead Candidate

Indication /
Platform Technology /
Molecule

Status

Preclinical Development

IND

Liver
Severe liver disease
SWEETS
SZN-043
Lead Candidate
IND 2021
2021
Intestine
IBD
SWAP
SZN-1326
Lead Candidate
IND 2022
2022
Retina
Retinopathy, AMD
SWAP
SWAP-4
Proof of Concept
Lung
IPF, COPD
TBD
TBD
Discovery Research
Inner Ear
Hearing loss
SWAP
TBD
Discovery Research

Surrozen’s novel approach to modulating the Wnt pathway may lead to therapeutics that reverse the effects of serious diseases by repairing damaged tissue, restoring organ function and renewing a patient’s health, and hope, for an improved quality of life.

Repair. Restore. Renew.